Your session is about to expire
← Back to Search
Study Summary
This trial will study the effects of a new drug called AZD6244 on patients with advanced cancer. They will be testing to see if the drug is safe and tolerable for patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 334 Patients • NCT01248247Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken part in another clinical trial with an experimental drug in the last 30 days.You have received radiation or chemotherapy treatment within the last 21 days.You have a severe and uncontrolled disease that affects your whole body.You have cancer that has spread to your brain or spinal cord, unless it is not causing any symptoms and you are not taking steroids or anticonvulsants.Your cancer has not responded to standard treatments.
- Group 1: AZD6244
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has AZD6244 attained the necessary regulatory clearance for general use?
"The safety of AZD6244 is rated a 1, as this initial trial has only provided limited evidence for safety and efficacy."
Are individuals aged under 50 capable of joining this medical experiment?
"This clinical trial is looking for individuals aged 18-99, with 368 studies dedicated to minors and 2609 trials targeting the elderly."
What prerequisites should prospective participants of this trial meet?
"To be eligible for this medical trial, participants must have some form of malignancy and fall between the ages of 18 to 99 years old. This research project is recruiting a total population size of 58 patients."
How many individuals have signed up for this experiment?
"This research project is no longer recruiting. It was posted on March 8th 2007 and last updated August 31st 2022. For those searching for other trials, there are 2820 studies admitting participants with malignancies, with 34 of them offering AZD6244 as an intervention."
Are recruitment efforts still underway for this clinical exploration?
"According to clinicaltrials.gov, this research project is not presently accepting participants; the first posting was on March 8th 2007 with a final update made in August 31st 2022. Nevertheless, there are 2854 other trials currently focusing on patient recruitment."
Could you please provide details on past experiments that have been done with AZD6244?
"Currently, 34 AZD6244 clinical trials are taking place and 5 of them have reached the final stage. While Philadelphia is home to a significant number of these studies, there are 1,005 sites worldwide examining this drug's efficacy."
Is this research a groundbreaking innovation in the field?
"Since 2007, AstraZeneca has been researching AZD6244 with the first trial involving 58 participants. Subsequently, this medication was approved for Phase 1 and there are currently 34 active trials in 33 countries across 156 cities."
Share this study with friends
Copy Link
Messenger